Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > Atracurium besylate

Atracurium besylate

pharmaceutical raw materials
Atracurium besylate structure

Atracurium besylate 

structure
  • CAS No:

    64228-81-5

  • Formula:

    C53H72N2O12.2C6H5O3S

  • Chemical Name:

    Atracurium besylate

  • Synonyms:

    Isoquinolinium,2,2′-[1,5-pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-,benzenesulfonate (1:2);Isoquinolinium,2,2′-[1,5-pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-,dibenzenesulfonate;Atracurium besylate;BW 33A;Atracurium dibesylate;Tracrium;Atracurium besilate;Atracurium dibesilate;Wellcome 33A74;Tracur

  • Categories:

    Chemical Reagents  >  Organic Reagents

Description

Atracurium Besylate is a neuromuscular blocking agent with ED95 of 0.2 mg/kg. Target: nAChRAtracurium besylate is a neuromuscular-blocking drug or skeletal muscle relaxant in the category of non-depolarizing neuromuscular-blocking drugs, used adjunctively in anesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Atracurium is classified as an intermediate-duration non-depolarizing neuromuscular-blocking agent [


Atracurium besylate is the bisbenzenesulfonate salt of atracurium. It has a role as a nicotinic antagonist and a muscle relaxant. It is a quaternary ammonium salt and an organosulfonate salt. It contains an atracurium.|A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.|Atracurium Besylate is a synthetic dibenzensulfonate derivative muscle relaxant, Atracurium Besylate acts as a non-depolarizing neuromuscular blocking agent, with short to intermediary duration of action and no significant cardiovascular effects. Not dependent on kidney function for elimination, it provides clinical advantages over other non-depolarizing, neuromuscular blocking agents. (NCI04)

Atracurium besylate Basic Attributes

1243.48

1242.500366

264-743-4

760047

DTXSID6022630

C28839

29334900

Characteristics

257.60000

11.32610

white powder

85-90 °C

H2O: ~27 mg/mL

2-8°C

Safety Information

NONH for all modes of transport

3

24/25

P260, P262, P264, P270, P271, P280, P284, P301+P310, P302+P350, P304+P340, P310, P320, P321, P322, P330, P361, P363, P403+P233, P405, P501

H300

|Danger|H300 (23.61%): Fatal if swallowed [Danger Acute toxicity, oral]|P260, P262, P264, P270, P271, P280, P284, P301+P310, P302+P350, P304+P340, P310, P320, P321, P322, P330, P361, P363, P403+P233, P405, and P501|Aggregated GHS information provided by 72 companies from 8 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.|H301 (95.79%): Toxic if swallowed [Danger Acute toxicity, oral]|P264, P270, P280, P301+P310, P305+P351+P338, P321, P330, P337+P313, P405, and P501|Aggregated GHS information provided by 95 companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Toxicity

Excessive doses can be expected to produce enhanced pharmacological effects. Overdosage may increase the risk of histamine release and cardiovascular effects, especially hypotension.

Drug Information

For use, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Atracurium is a nondepolarizing skeletal muscle relaxant. Atracurium can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored to assess degree of muscle relaxation. The duration of neuromuscular block produced by Atracurium is approximately one third to one half the duration of block by d-tubocurarine, metocurine, and pancuronium at initially equipotent doses. As with other nondepolarizing neuromuscular blockers, the time to onset of paralysis decreases and the duration of maximum effect increases with increasing doses of Atracurium. Repeated administration of maintenance doses of Atracurium has no cumulative effect on the duration of neuromuscular block if recovery is allowed to begin prior to repeat dosing. Moreover, the time needed to recover from repeat doses does not change with additional doses. Repeat doses can therefore be administered at relatively regular intervals with predictable results.

Drugs that interrupt transmission at the skeletal neuromuscular junction without causing depolarization of the motor end plate. They prevent acetylcholine from triggering muscle contraction and are used as muscle relaxants during electroshock treatments, in convulsive states, and as anesthesia adjuvants. (See all compounds classified as Neuromuscular Nondepolarizing Agents.)|Drugs that bind to nicotinic cholinergic receptors (RECEPTORS, NICOTINIC) and block the actions of acetylcholine or cholinergic agonists. Nicotinic antagonists block synaptic transmission at autonomic ganglia, the skeletal neuromuscular junction, and at central nervous system nicotinic synapses. (See all compounds classified as Nicotinic Antagonists.)

The elimination half-life is approximately 20 minutes.

Atracurium antagonizes the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. This antagonism is inhibited, and neuromuscular block reversed, by acetylcholinesterase inhibitors such as neostigmine, edrophonium, and pyridostigmine.

33 A 74

Atracurium besylate Use and Manufacturing

Uses

Non-depolarizing muscle relaxants are 2.5 times more effective than myostatin, but the duration of action is shorter. Used for various surgical operations, especially tracheal intubation and caesarean section. Skeletal muscle relaxant for general anesthesia

Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients

Computed Properties

Molecular Weight:1243.5
Hydrogen Bond Acceptor Count:18
Rotatable Bond Count:26
Exact Mass:1242.50040612
Monoisotopic Mass:1242.50040612
Topological Polar Surface Area:258
Heavy Atom Count:87
Complexity:1560
Undefined Atom Stereocenter Count:4
Covalently-Bonded Unit Count:3
Compound Is Canonicalized:Yes

Drug Function and Efficacy

This product is a highly selective, competitive (non-depolarizing) neuromuscular junction blocker. It works mainly by competing for cholinergic receptors and blocking the transmission of acetylcholine. It undergoes Hofmann elimination and naturally degrades at plasma pH and body temperature.

This ingredient has been used in drugs with the following functions (note: it does not mean that the ingredient itself has the following health functions)

Related Drugs

Registered Holders

  • GLAND PHARMA LTD

    India India
    Active
  • TAPI NL B.V.

    France France
    Active
  • Beijing Ansenbo Pharmaceutical Technology Co., Ltd.

    China China
    Active

Recommended Suppliers of Atracurium besylate

Latest News on Atracurium besylate

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.